Catalyst Wire Dossier Catalyst Wire Dossier

VLA1601

· Valneva Austria GmbH
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VLA1601, covering 2026-03-09 to 2026-03-09. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults [Phase 1]

See pricing